ClinicalTrials.gg
CompletedNCT07342881Updated Aug 21, 2026

Single Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Participants With Renal Impairment and in Healthy Participants With Normal Renal Function

A Phase 1 interventional study of Pevifoscorvir Sodium (ALG-000184) in Chronic Hepatitis B Infection, sponsored by Aligos Therapeutics. Completed at 2 sites in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-21.

Sponsored by Aligos Therapeutics · Phase 1, Interventional, and Treatment

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This is a Phase 1 non-randomized, open-label, single-dose study of pevifoscorvir sodium (also known as ALG-000184) in participants with severe renal impairment (Part 1), in participants with mild or moderate renal impairment (Optional Part 2) and in participants without renal impairment (Parts 1 and 2), matched for age, body weight and, to the extent possible, for sex.

02

Conditions studied

  • Chronic Hepatitis B Infection

Browse trials for

Keywords

  • Chronic Hepatitis B Infection
03

In context

Hepatitis B, Chronic

895 studies on the registry are indexed under Hepatitis B, Chronic; 151 are open to participants now.

This study's enrollment of 12 is below the median of 100 across 659 interventional studies indexed under Hepatitis B, Chronic.

Browse Hepatitis B, Chronic studies →

Lead sponsor

Aligos Therapeutics is the lead sponsor of 15 studies on the registry; none are open to participants now.

Of its 7 completed or terminated interventional studies of FDA-regulated products, 2 (29%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and Female between 18 and 75 years old
  2. (BMI) 17.5 to 40.0 kg/m\^2 and a total body weight >50 kg (110 lb)
  3. Female subjects must either be not of or if they are a woman of childbearing potential, they are only eligible if they and any non-sterile, male sexual partners agree to use highly effective therapy

Inclusion Criteria for Subjects with Normal Renal Function:

  1. Good general health as defined by no abnormalities identified by Medical History and a vital signs, clinical laboratory and 12-lead (ECG) assessment
  2. Subjects must fit the demographic-matching criteria including body weight, age, and to the extent possible, sex
  3. Normal renal function (estimated [eGFR] ≥90 mL/min) with no known or suspected renal impairment

Inclusion Criteria for Subjects with Impaired Renal Function:

  1. Subject satisfies the eGFR criteria for renal impairment classification within 28 days of study drug administration
  2. Any form of renal impairment except acute nephritic syndrome (subjects with history of previous nephritic syndrome but in remission can be included).
  3. Stable concomitant medications for the management of an individual subject's medical history for at least 28 days prior to screening
  4. Subjects must have a 12-lead ECG and vital signs assessment that meet the protocol criteria

Exclusion criteria

Exclusion Criteria for All Subjects:

  1. Subjects with any current or previous illness that, in the opinion of the Investigator, might confound the results of the study or pose an additional risk in administering study drug to the subject or that could prevent, limit, or confound the protocol specified assessments or study results and interpretation
  2. Subjects with a past history of cardiac arrhythmias, risk factors for Torsade de Pointes syndrome (e.g., hypokalemia, family history of long Syndrome) or recent history or clinical evidence at screening of significant (subjects with normal renal function) or unstable (subjects with renal impairment) cardiac disease etc.
  3. Subjects with a history of drug allergy
  4. Subjects with a recent (within 1 year of randomization) history or current evidence of drug abuse or recreational drug use
  5. Excessive use of alcohol defined as regular consumption of ≥14 units/ week for women and ≥21 units/week for men
  6. Unwilling to abstain from alcohol use for 48 hours prior to start of the study through end of study follow up
  7. Subjects with Hepatitis A, B, C, E or -1/HIV-2 infection or acute infections such as SARS- CoV-2 infection
  8. Subjects with (ALT) or aspartate aminotransferase (AST) values >2x (ULN)
  9. Subjects with (total, direct) >1.5x ULN (unless Gilbert's is suspected)
  10. Positive pregnancy test; females must not be pregnant at enrollment

Exclusion Criteria for Subjects with Normal Renal Function:

1. \<10 g/dL

Exclusion Criteria for Subjects with Impaired Renal Function:

  1. Participants requiring hemodialysis and/or peritoneal dialysis
  2. Hemoglobin \<9 g/dL
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Subjects with renal Impairment

    Subjects with renal impairment will receive single oral doses of 100 mg pevifoscorvir sodium. Subjects will be followed up for 14 days after the administration of study drug.

    Drug: Pevifoscorvir Sodium (ALG-000184)

  • Experimental
    Subjects without renal impairment

    Subjects without renal impairment will receive single oral doses of 100 mg pevifoscorvir sodium. Subjects will be followed up for 14 days after the administration of study drug.

    Drug: Pevifoscorvir Sodium (ALG-000184)

Interventions

06

What researchers measure

Primary outcomes

  1. Area under the concentration time curve [AUC]

    Plasma PK parameters in each cohort of total ALG-001075 and the metabolite ALG-000302

    Time frame: Up to 4 days

  2. Maximum plasma concentration [Cmax]

    Plasma PK parameters in each cohort of total ALG-001075 and the metabolite ALG-000302

    Time frame: Up to 4 Days

  3. Minimum plasma concentration [Cmin]

    Plasma PK parameters in each cohort of total ALG-001075 and the metabolite ALG-000302

    Time frame: Up to 4 Days

  4. C0 [predose]

    Plasma PK parameters in each cohort of total ALG-001075 and the metabolite ALG-000302

    Time frame: Up to 4 days

  5. Half-life [t1/2]

    Plasma PK parameters in each cohort of total ALG-001075 and the metabolite ALG-000302

    Time frame: Up to 4 Days

  6. Time to maximum plasma concentration [Tmax]

    Plasma PK parameters in each cohort of total ALG-001075 and the metabolite ALG-000302

    Time frame: Up to 4 Days

  7. Apparent Clearance (CL/F)

    Plasma PK parameters in each cohort of total ALG-001075 and the metabolite ALG-000302

    Time frame: Up to 4 Days

  8. Apparent Volume of Distribution (V/F)

    Plasma PK parameters in each cohort of total ALG-001075 and the metabolite ALG-000302

    Time frame: Up to 4 Days

  9. Total Amount of Drug Excreted in Urine (Ae)

    Urine PK parameters in each cohort of total ALG-001075 and the metabolite ALG-000302

    Time frame: Up to 4 Days

  10. Renal Clearance (CLr)

    Urine PK parameters in each cohort of total ALG-001075 and the metabolite ALG-000302

    Time frame: Up to 4 Days

Secondary outcomes

  1. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]

    The number and severity of treatment emergent events in subjects with renal impairment and subjects with normal renal function as assessed by DAIDS v2.1

    Time frame: Up to 15 days

07

Study locations

2 sites
  • Orlando Clinical Research Center
    Orlando, Florida 32809, United States
  • Genesis Clinical Trials
    Tampa, Florida 33603, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07342881
Lead sponsor
Aligos Therapeutics
Responsible party
Sponsor
First posted
Jan 15, 2026
Start date
Mar 10, 2026
Primary completion
Jul 29, 2026
Completion
Jul 29, 2026
Last update
Aug 21, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pevifoscorvir sodium

Start the discussion